Skip to main content
Top
Published in: BMC Gastroenterology 1/2023

Open Access 01-12-2023 | Cholangiocarcinoma | Research

Prognostic model for oversurvival and tumor-specific survival prediction in patients with advanced extrahepatic cholangiocarcinoma: a population-based analysis

Authors: Yu Zhang, Chunzhong Qiao, Peng Zhao, Changhe Zhang

Published in: BMC Gastroenterology | Issue 1/2023

Login to get access

Abstract

Background

The prognosis of patients with extrahepatic cholangiocarcinoma (ECCA) must be determined with precision. However, the usual TNM staging system has the drawback of ignoring age, adjuvant therapy, and gender and lacks the ability to more correctly predict patient prognosis. Therefore, we determine the risk factors of survival for patients with advanced ECCA patients and developed brand-new nomograms to forecast patients with advanced ECCA’s overall survival (OS) and cancer-specific survival (CSS).

Method

From the Epidemiology and End Results (SEER) database, patients with advanced ECCA were chosen and randomly assigned in a ratio of 6:4 to the training and validation subgroups. The cumulative incidence function (CIF) difference between groups was confirmed by applying Gray’s and Fine test and competing risk analyses. Next, the cancer-specific survival (CSS) and overall survival (OS) nomograms for advanced ECCA were developed and validated.

Results

In accordance with the selection criteria, 403 patients with advanced ECCA were acquired from the SEER database and then split at random into two groups: a training group (n = 241) and a validation group (n = 162). The 1-, 2-, and 3-year cancer-specific mortality rates were 58.7, 74.2, and 78.0%, respectively, while the matching mortality rates for the competition were 10.0, 13.8, and 15.0%. Nomograms were generated for estimating OS and CSS, and they were assessed using the ROC curve and the C-index. The calibration curves showed that there was a fair amount of agreement between the expected and actual probabilities of OS and CSS. Additionally, greater areas under the ROC curve were seen in the newly developed nomograms for OS and CSS when compared to the 7th AJCC staging system. The advanced ECCA patients were divided into groupings with an elevated risk and those with a low risk and the Kaplan-Meier method was used for the survival analysis, which showed that survival time was shorter in the high-risk group than in the low-risk group.

Conclusion

The proposed nomograms have good predictive ability. The nomograms may can help doctors determine the prognosis of patients with advanced ECCA as well as provide more precise treatment plans for them.
Appendix
Available only for authorised users
Literature
1.
go back to reference Elvevi A, Laffusa A, Scaravaglio M, et al. Clinical treatment of cholangiocarcinoma: an updated comprehensive review. Ann Hepatol. 2022;27(5):100737.CrossRefPubMed Elvevi A, Laffusa A, Scaravaglio M, et al. Clinical treatment of cholangiocarcinoma: an updated comprehensive review. Ann Hepatol. 2022;27(5):100737.CrossRefPubMed
2.
go back to reference Rimini M, Puzzoni M, Pedica F, et al. Cholangiocarcinoma: new perspectives for new horizons. Expert Rev Gastroenterol Hepatol. 2021;15(12):1367–83.CrossRefPubMed Rimini M, Puzzoni M, Pedica F, et al. Cholangiocarcinoma: new perspectives for new horizons. Expert Rev Gastroenterol Hepatol. 2021;15(12):1367–83.CrossRefPubMed
3.
go back to reference Yang JD, Ghoz H, Aboelsoud MM, et al. DNA methylation markers for detection of Cholangiocarcinoma: discovery, validation, and clinical testing in biliary brushings and plasma. Hepatol Commun. 2021;5(8):1448–59.CrossRefPubMedPubMedCentral Yang JD, Ghoz H, Aboelsoud MM, et al. DNA methylation markers for detection of Cholangiocarcinoma: discovery, validation, and clinical testing in biliary brushings and plasma. Hepatol Commun. 2021;5(8):1448–59.CrossRefPubMedPubMedCentral
5.
go back to reference Ercolani G, Dazzi A, Giovinazzo F, et al. Intrahepatic, peri-hilar and distal cholangiocarcinoma: three different locations of the same tumor or three different tumors? Eur J Surg Oncol. 2015;41(9):1162–9.CrossRefPubMed Ercolani G, Dazzi A, Giovinazzo F, et al. Intrahepatic, peri-hilar and distal cholangiocarcinoma: three different locations of the same tumor or three different tumors? Eur J Surg Oncol. 2015;41(9):1162–9.CrossRefPubMed
6.
go back to reference Mansour JC, Aloia TA, Crane CH, Heimbach JK, Nagino M, Vauthey JN. Hilar cholangiocarcinoma: expert consensus statement. HPB (Oxford). 2015;17(8):691–9.CrossRefPubMedPubMedCentral Mansour JC, Aloia TA, Crane CH, Heimbach JK, Nagino M, Vauthey JN. Hilar cholangiocarcinoma: expert consensus statement. HPB (Oxford). 2015;17(8):691–9.CrossRefPubMedPubMedCentral
8.
go back to reference Boakye D, Günther K, Niedermaier T, Haug U, Ahrens W, Nagrani R. Associations between comorbidities and advanced stage diagnosis of lung, breast, colorectal, and prostate cancer: a systematic review and meta-analysis. Cancer Epidemiol. 2021;75:102054.CrossRefPubMed Boakye D, Günther K, Niedermaier T, Haug U, Ahrens W, Nagrani R. Associations between comorbidities and advanced stage diagnosis of lung, breast, colorectal, and prostate cancer: a systematic review and meta-analysis. Cancer Epidemiol. 2021;75:102054.CrossRefPubMed
9.
go back to reference Sarfati D, Koczwara B, Jackson C. The impact of comorbidity on cancer and its treatment. CA Cancer J Clin. 2016;66(4):337–50.CrossRefPubMed Sarfati D, Koczwara B, Jackson C. The impact of comorbidity on cancer and its treatment. CA Cancer J Clin. 2016;66(4):337–50.CrossRefPubMed
10.
go back to reference Boakye D, Rillmann B, Walter V, Jansen L, Hoffmeister M, Brenner H. Impact of comorbidity and frailty on prognosis in colorectal cancer patients: a systematic review and meta-analysis. Cancer Treat Rev. 2018;64:30–9.CrossRefPubMed Boakye D, Rillmann B, Walter V, Jansen L, Hoffmeister M, Brenner H. Impact of comorbidity and frailty on prognosis in colorectal cancer patients: a systematic review and meta-analysis. Cancer Treat Rev. 2018;64:30–9.CrossRefPubMed
11.
go back to reference Cheng Y, Zhang P, Huang Y, et al. Development and validation of nomograms to predict survival in patients with invasive micropapillary carcinoma of the breast. BMJ Open. 2023;13(2):e065312.CrossRefPubMedPubMedCentral Cheng Y, Zhang P, Huang Y, et al. Development and validation of nomograms to predict survival in patients with invasive micropapillary carcinoma of the breast. BMJ Open. 2023;13(2):e065312.CrossRefPubMedPubMedCentral
12.
go back to reference Wu J, Zhang H, Li L, et al. A nomogram for predicting overall survival in patients with low-grade endometrial stromal sarcoma: a population-based analysis. Cancer Commun (Lond). 2020;40(7):301–12.CrossRefPubMed Wu J, Zhang H, Li L, et al. A nomogram for predicting overall survival in patients with low-grade endometrial stromal sarcoma: a population-based analysis. Cancer Commun (Lond). 2020;40(7):301–12.CrossRefPubMed
13.
go back to reference Forner A, Vidili G, Rengo M, Bujanda L, Ponz-Sarvisé M, Lamarca A. Clinical presentation, diagnosis and staging of cholangiocarcinoma. Liver Int. 2019;39(Suppl 1):98–107.CrossRefPubMed Forner A, Vidili G, Rengo M, Bujanda L, Ponz-Sarvisé M, Lamarca A. Clinical presentation, diagnosis and staging of cholangiocarcinoma. Liver Int. 2019;39(Suppl 1):98–107.CrossRefPubMed
14.
go back to reference Zhang W, Ji L, Wang X, et al. Nomogram predicts risk and prognostic factors for bone metastasis of pancreatic Cancer: a population-based analysis. Front Endocrinol (Lausanne). 2022;12:752176.CrossRefPubMed Zhang W, Ji L, Wang X, et al. Nomogram predicts risk and prognostic factors for bone metastasis of pancreatic Cancer: a population-based analysis. Front Endocrinol (Lausanne). 2022;12:752176.CrossRefPubMed
15.
go back to reference Golse N, Nunez J, Mazzotta A, et al. Personalized preoperative nomograms predicting postoperative risks after resection of Perihilar Cholangiocarcinoma. World J Surg. 2020;44(10):3449–60.CrossRefPubMed Golse N, Nunez J, Mazzotta A, et al. Personalized preoperative nomograms predicting postoperative risks after resection of Perihilar Cholangiocarcinoma. World J Surg. 2020;44(10):3449–60.CrossRefPubMed
16.
go back to reference Zhang T, Lai M, Wei Y, et al. Nomograms for predicting overall survival and cancer-specific survival in patients with invasive micropapillary carcinoma: based on the SEER database [published online ahead of print, 2023 mar 16]. Asian J Surg. 2023;S1015-9584(23):00263–4. Zhang T, Lai M, Wei Y, et al. Nomograms for predicting overall survival and cancer-specific survival in patients with invasive micropapillary carcinoma: based on the SEER database [published online ahead of print, 2023 mar 16]. Asian J Surg. 2023;S1015-9584(23):00263–4.
17.
go back to reference Chen Y, Yu C, Chen D, et al. A prognostic nomogram based on risk assessment for invasive micropapillary carcinoma of the breast after surgery. Cancer Med. 2023;12(7):8050–62.CrossRefPubMedPubMedCentral Chen Y, Yu C, Chen D, et al. A prognostic nomogram based on risk assessment for invasive micropapillary carcinoma of the breast after surgery. Cancer Med. 2023;12(7):8050–62.CrossRefPubMedPubMedCentral
18.
go back to reference Doll KM, Rademaker A, Sosa JA. Practical guide to surgical data sets: surveillance, epidemiology, and end results (SEER) database. JAMA Surg. 2018;153(6):588–9.CrossRefPubMed Doll KM, Rademaker A, Sosa JA. Practical guide to surgical data sets: surveillance, epidemiology, and end results (SEER) database. JAMA Surg. 2018;153(6):588–9.CrossRefPubMed
19.
go back to reference He C, Cai Z, Zhang Y, Lin X. Prognostic model to predict Cancer-specific survival for patients with gallbladder carcinoma after surgery: a population-based analysis. Front Oncol. 2019;9:1329 Published 12 Dec 2019.CrossRefPubMedPubMedCentral He C, Cai Z, Zhang Y, Lin X. Prognostic model to predict Cancer-specific survival for patients with gallbladder carcinoma after surgery: a population-based analysis. Front Oncol. 2019;9:1329 Published 12 Dec 2019.CrossRefPubMedPubMedCentral
20.
go back to reference Pencina MJ, D’Agostino RB. Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med. 2004;23(13):2109–23.CrossRefPubMed Pencina MJ, D’Agostino RB. Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med. 2004;23(13):2109–23.CrossRefPubMed
21.
go back to reference Vickers AJ, Cronin AM, Elkin EB, Gonen M. Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers. BMC Med Inform Decis Mak. 2008;8:53.CrossRefPubMedPubMedCentral Vickers AJ, Cronin AM, Elkin EB, Gonen M. Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers. BMC Med Inform Decis Mak. 2008;8:53.CrossRefPubMedPubMedCentral
22.
go back to reference Khan SA, Tavolari S, Brandi G. Cholangiocarcinoma: epidemiology and risk factors. Liver Int. 2019;39(Suppl 1):19–31.CrossRefPubMed Khan SA, Tavolari S, Brandi G. Cholangiocarcinoma: epidemiology and risk factors. Liver Int. 2019;39(Suppl 1):19–31.CrossRefPubMed
23.
go back to reference Zhao F, Yang D, He J, Ju X, Ding Y, Li X. Establishment and validation of a prognostic nomogram for extrahepatic cholangiocarcinoma. Front Oncol. 2022;12:1007538 Published 24 Nov 2022.CrossRefPubMedPubMedCentral Zhao F, Yang D, He J, Ju X, Ding Y, Li X. Establishment and validation of a prognostic nomogram for extrahepatic cholangiocarcinoma. Front Oncol. 2022;12:1007538 Published 24 Nov 2022.CrossRefPubMedPubMedCentral
24.
go back to reference Eguchi T, Bains S, Lee MC, et al. Impact of increasing age on cause-specific mortality and morbidity in patients with stage I non-small-cell lung Cancer: a competing risks analysis. J Clin Oncol. 2017;35(3):281–90.CrossRefPubMed Eguchi T, Bains S, Lee MC, et al. Impact of increasing age on cause-specific mortality and morbidity in patients with stage I non-small-cell lung Cancer: a competing risks analysis. J Clin Oncol. 2017;35(3):281–90.CrossRefPubMed
25.
go back to reference Yu C, Zhang Y. Establishment of prognostic nomogram for elderly colorectal cancer patients: a SEER database analysis. BMC Gastroenterol. 2020;20(1):347 Published 20 Oct 2020.CrossRefPubMedPubMedCentral Yu C, Zhang Y. Establishment of prognostic nomogram for elderly colorectal cancer patients: a SEER database analysis. BMC Gastroenterol. 2020;20(1):347 Published 20 Oct 2020.CrossRefPubMedPubMedCentral
26.
27.
go back to reference Kim HJ, Kang TU, Swan H, et al. Incidence and prognosis of subsequent Cholangiocarcinoma in patients with hepatic resection for bile duct stones. Dig Dis Sci. 2018;63(12):3465–73.CrossRefPubMed Kim HJ, Kang TU, Swan H, et al. Incidence and prognosis of subsequent Cholangiocarcinoma in patients with hepatic resection for bile duct stones. Dig Dis Sci. 2018;63(12):3465–73.CrossRefPubMed
28.
go back to reference Yu Z, Liu Q, Liao H, et al. Prognostic nomogram for predicting cancer-specific survival in patients with resected hilar cholangiocarcinoma: a large cohort study. J Gastrointest Oncol. 2022;13(2):833–46.CrossRefPubMedPubMedCentral Yu Z, Liu Q, Liao H, et al. Prognostic nomogram for predicting cancer-specific survival in patients with resected hilar cholangiocarcinoma: a large cohort study. J Gastrointest Oncol. 2022;13(2):833–46.CrossRefPubMedPubMedCentral
29.
go back to reference Kayahara M, Nagakawa T, Ohta T, et al. Role of nodal involvement and the periductal soft-tissue margin in middle and distal bile duct cancer. Ann Surg. 1999;229(1):76–83.CrossRefPubMedPubMedCentral Kayahara M, Nagakawa T, Ohta T, et al. Role of nodal involvement and the periductal soft-tissue margin in middle and distal bile duct cancer. Ann Surg. 1999;229(1):76–83.CrossRefPubMedPubMedCentral
30.
go back to reference DeOliveira ML, Cunningham SC, Cameron JL, et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg. 2007;245(5):755–62.CrossRefPubMedPubMedCentral DeOliveira ML, Cunningham SC, Cameron JL, et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg. 2007;245(5):755–62.CrossRefPubMedPubMedCentral
32.
go back to reference Zender L, Malek NP. Diagnostik und Therapie des cholangiozellulären Karzinoms [diagnostics and treatment of cholangiocellular carcinoma]. Internist (Berl). 2016;57(12):1191–205.CrossRefPubMed Zender L, Malek NP. Diagnostik und Therapie des cholangiozellulären Karzinoms [diagnostics and treatment of cholangiocellular carcinoma]. Internist (Berl). 2016;57(12):1191–205.CrossRefPubMed
33.
go back to reference Greenberg PL, Attar E, Bennett JM, et al. NCCN clinical practice guidelines in oncology: myelodysplastic syndromes. J Natl Compr Cancer Netw. 2011;9(1):30–56.CrossRef Greenberg PL, Attar E, Bennett JM, et al. NCCN clinical practice guidelines in oncology: myelodysplastic syndromes. J Natl Compr Cancer Netw. 2011;9(1):30–56.CrossRef
35.
36.
go back to reference Lv J, Liu YY, Jia YT, et al. A nomogram model for predicting prognosis of obstructive colorectal cancer. World J Surg Oncol. 2021;19(1):337 Published 2021 Dec 2.CrossRefPubMedPubMedCentral Lv J, Liu YY, Jia YT, et al. A nomogram model for predicting prognosis of obstructive colorectal cancer. World J Surg Oncol. 2021;19(1):337 Published 2021 Dec 2.CrossRefPubMedPubMedCentral
37.
go back to reference Song K, Song J, Chen F, Lin K, Ma X, Jiang J. Prognostic nomograms for predicting overall and cancer-specific survival of high-grade osteosarcoma patients. J Bone Oncol. 2018;13:106–13 Published 2018 Oct 4.CrossRefPubMedPubMedCentral Song K, Song J, Chen F, Lin K, Ma X, Jiang J. Prognostic nomograms for predicting overall and cancer-specific survival of high-grade osteosarcoma patients. J Bone Oncol. 2018;13:106–13 Published 2018 Oct 4.CrossRefPubMedPubMedCentral
38.
go back to reference Zuo Z, Zhang G, Song P, et al. Survival nomogram for stage IB non-small-cell lung Cancer patients, based on the SEER database and an external validation cohort. Ann Surg Oncol. 2021;28(7):3941–50.CrossRefPubMed Zuo Z, Zhang G, Song P, et al. Survival nomogram for stage IB non-small-cell lung Cancer patients, based on the SEER database and an external validation cohort. Ann Surg Oncol. 2021;28(7):3941–50.CrossRefPubMed
39.
go back to reference Tella SH, Kommalapati A, Yadav S, et al. Novel staging system using carbohydrate antigen (CA) 19-9 in extra-hepatic cholangiocarcinoma and its implications on overall survival. Eur J Surg Oncol. 2020;46(5):789–95.CrossRefPubMed Tella SH, Kommalapati A, Yadav S, et al. Novel staging system using carbohydrate antigen (CA) 19-9 in extra-hepatic cholangiocarcinoma and its implications on overall survival. Eur J Surg Oncol. 2020;46(5):789–95.CrossRefPubMed
Metadata
Title
Prognostic model for oversurvival and tumor-specific survival prediction in patients with advanced extrahepatic cholangiocarcinoma: a population-based analysis
Authors
Yu Zhang
Chunzhong Qiao
Peng Zhao
Changhe Zhang
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2023
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/s12876-023-03017-6

Other articles of this Issue 1/2023

BMC Gastroenterology 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.